この専門家をプロジェクトに採用したいですか? 見積もりを依頼 無料で。
プロフィール詳細
専門分野
サービス
職務経験
Teaching Asistant
Monash University
10月 2020 - 10月 2024
学歴
PhD
Monash University Malaysia
10月 2020 - 12月 2024 ![]()
Bachelor of Science (Hons) (School of Science)
Monash University Malaysia
2016 - 2019 ![]()
認定資格
- 認定資格の詳細は未入力です。
出版物
JOURNAL ARTICLE
Asuka Joy Tobuse, Christine Shing Wei Law, Chun Keng Thy, Jason Jonah James, Chin Fei Chee, Keng Yoon Yeong (2024). Indazole derivatives as selective inhibitors of butyrylcholinesterase with effective blood-brain-barrier permeability profile . Medicinal Chemistry Research.
Brendan Su Mee Hui, Lee Rui Zhi, Thaarvena Retinasamy, Alina Arulsamy, Christine Shing Wei Law, Mohd. Farooq Shaikh, Keng Yoon Yeong (2023). The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review . Journal of Alzheimer's Disease.
Ozum Ozturk, Fathima Manaal Farouk, Luyi Ooi, Christine Shing Wei Law, Muhammed Tilahun Muhammed, Esin Aki-Yalcin, Keng Yoon Yeong (2022). Synthesis of novel carboxamide- and carbohydrazide-benzimidazoles as selective butyrylcholinesterase inhibitors . Molecular Diversity.
Christine Shing Wei Law, Keng Yoon Yeong (2022). Current trends of benzothiazoles in drug discovery: a patent review (2015–2020) . Expert Opinion on Therapeutic Patents.
Christine S. W. Law, Keng Y. Yeong (2021). Benzimidazoles in Drug Discovery: A Patent Review . ChemMedChem.
Christine Shing Wei Law, Keng Yoon Yeong (2021). Repurposing Antihypertensive Drugs for the Management of Alzheimer’s Disease . Current Medicinal Chemistry.
Fathima Manaal Farouk, Luyi Ooi, Christine Shing Wei Law, Keng Yoon Yeong (2020). Dual‐Target‐Directed Ligand Displaying Selective Butyrylcholinesterase Inhibitory and Neurite Promoting Activities as a Potential Therapeutic for Alzheimer's Disease . ChemistrySelect.